Under construction – not a live service
Sign in
Taking people in United StatesPhase 3

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Key facts

Where
Auburn Hills, Bakersfield, Birmingham, Boise, Bryant, Cary, Charlotte, Chicago, Clarksville, Cumming, Dallas, Denver, Doral, Fremont, Frisco, Greenville, Hollywood, Indianapolis, Kissimmee, Los Angeles, Louisville, Lynnwood, Macon, Mason, Miami, Miami Lakes, Missoula, Omaha, Palm Springs, Pflugerville, Plymouth Meeting, Pompano Beach, Rockville, Saint Joseph, San Antonio, San Diego, Sanford, Savannah, Scottsdale, Smyrna, South Jordan, Springville, Sweetwater, Troy, Verona, Wheat Ridge, and Woodbury, United StatesSee the 54 sites
Phase
Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 17 years old?

Source: NCT07133308, who can take part

Where in United States

  • Oakland Hills DermatologyAuburn Hills, United StatesContact: Head Regulatory AffairsTaking people
  • Kern Research, IncBakersfield, United StatesContact: Head Regulatory AffairsTaking people
  • Total Skin and Beauty Dermatology CenterBirmingham, United StatesContact: Head Regulatory AffairsTaking people
  • ASR, LLCBoise, United StatesContact: Head Regulatory AffairsTaking people
  • Dermatology Trial AssociatesBryant, United StatesContact: Head Regulatory AffairsTaking people
  • Revival Research Institute, Llc - Cary, NcCary, United StatesContact: Head Regulatory AffairsTaking people
  • Darst DermatologyCharlotte, United StatesContact: Head Regulatory AffairsTaking people
  • DeNova ResearchChicago, United StatesContact: Head Regulatory AffairsTaking people
  • Ds Research - IndianaClarksville, United StatesContact: Head Regulatory AffairsTaking people
  • Cleaver Medical Group DermatologyCumming, United StatesContact: Head Regulatory AffairsTaking people
  • Dermatology Treatment and Research Center - DallasDallas, United StatesContact: Head Regulatory AffairsTaking people
  • Colorado Medical Research CenterDenver, United StatesContact: Head Regulatory AffairsTaking people
  • D&H Doral Research CenterDoral, United StatesContact: Head Regulatory AffairsTaking people
  • Center For Dermatology Clinical Research, Inc.Fremont, United StatesContact: Head Regulatory AffairsTaking people
  • North Texas Center for Clinical ResearchFrisco, United StatesContact: Head Regulatory AffairsTaking people
  • Tribe Clinical Research LLCGreenville, United StatesContact: Head Regulatory AffairsTaking people
  • Skin Care Research, Llc - HollywoodHollywood, United StatesContact: Head Regulatory AffairsTaking people
  • Dawes Fretzin Clinical Research Group, LLCIndianapolis, United StatesContact: Head Regulatory AffairsTaking people
  • Ilumina Medical Research LLCKissimmee, United StatesContact: Head Regulatory AffairsTaking people
  • Dermatology Research AssociatesLos Angeles, United StatesContact: Head Regulatory AffairsTaking people
  • Ds Research - KentuckyLouisville, United StatesContact: Head Regulatory AffairsTaking people
  • National Eagle Research, LlcLynnwood, United StatesContact: Head Regulatory AffairsTaking people
  • Skin Care Physicians of GeorgiaMacon, United StatesContact: Head Regulatory AffairsTaking people
  • Dermatologists of Southwest OhioMason, United StatesContact: Head Regulatory AffairsTaking people
  • Advance Research Center, LlcMiami, United StatesContact: Head Regulatory AffairsTaking people
  • All X Ray Diagnostic Services CorpMiami, United StatesContact: Head Regulatory AffairsTaking people
  • Florida International Medical ResearchMiami, United StatesContact: Head Regulatory AffairsTaking people
  • Florida Pharmaceutical Research And Associates, Inc.Miami, United StatesContact: Head Regulatory AffairsTaking people
  • L&C Professional Medical Research InstituteMiami, United StatesContact: Head Regulatory AffairsTaking people
  • Millennium Medical Research LLCMiami, United StatesContact: Head Regulatory AffairsTaking people
  • Pediatric Skin Research LlcMiami, United StatesContact: Head Regulatory AffairsTaking people
  • Valencia Medical & Research CenterMiami, United StatesContact: Head Regulatory AffairsTaking people
  • Barroso Medical Services LlcMiami Lakes, United StatesContact: Head Regulatory AffairsTaking people
  • Boeson Research MSOMissoula, United StatesContact: Head Regulatory AffairsTaking people
  • Skin Specialists, PCOmaha, United StatesContact: Head Regulatory AffairsTaking people
  • Palmtree Clinical ResearchPalm Springs, United StatesContact: Head Regulatory AffairsTaking people
  • Austin Institute for Clinical Research, Inc.Pflugerville, United StatesContact: Head Regulatory AffairsTaking people
  • Dermatology Associates of Plymouth MeetingPlymouth Meeting, United StatesContact: Head Regulatory AffairsTaking people
  • Nexus Research LlcPompano Beach, United StatesContact: Head Regulatory AffairsTaking people
  • U.S. Dermatology Partners RockvilleRockville, United StatesContact: Head Regulatory AffairsTaking people
  • Medisearch Clinical TrialsSaint Joseph, United StatesContact: Head Regulatory AffairsTaking people
  • Texas Dermatology and Laser SpecialistsSan Antonio, United StatesContact: Head Regulatory AffairsTaking people
  • Paradigm Clinical Research - San DiegoSan Diego, United StatesContact: Head Regulatory AffairsTaking people
  • International Clinical Research Us Llc - SanfordSanford, United StatesContact: Head Regulatory AffairsTaking people
  • Georgia Skin & Cancer ClinicSavannah, United StatesContact: Head Regulatory AffairsTaking people
  • Avacare - Cct Research - Center For Dermatology And Plastic SurgeryScottsdale, United StatesContact: Head Regulatory AffairsTaking people
  • Delricht Research - SmyrnaSmyrna, United StatesContact: Head Regulatory AffairsTaking people
  • Jordan Valley DermatologySouth Jordan, United StatesContact: Head Regulatory AffairsTaking people
  • Avacare - Cct Research - Springville DermatologySpringville, United StatesContact: Head Regulatory AffairsTaking people
  • LENUS Research & Medical Group, LLCSweetwater, United StatesContact: Head Regulatory AffairsTaking people
  • Revival Research Institute, Llc - Troy, MiTroy, United StatesContact: Head Regulatory AffairsTaking people
  • Schweiger Dermatology & Allergy - VeronaVerona, United StatesContact: Head Regulatory AffairsTaking people
  • Paradigm Clinical Research - Wheat RidgeWheat Ridge, United StatesContact: Head Regulatory AffairsTaking people
  • Vitality Clinical TrialsWoodbury, United StatesContact: Head Regulatory AffairsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Sun Pharmaceutical Industries, Inc.
Trial code
NCT07133308
Record updated
28 January 2026
Original description
This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.Read full original descriptionShow less

A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescent Patients With Severe Alopecia Areata With an Open-label Extension Period

This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.

Inclusion: Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years; Between 12 to <18 years of age; At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50; Willing to comply with the study visits and requirements of the study protocol.

Exclusion: Treatment with other medications or agents within 28 days of Baseline or during the study that may affect hair regrowth or immune response; Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug; Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis at Screening and/or Baseline; Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.

ClinicalTrials.gov NCT07133308